Recruiting studies: Immunoglobulin Prophylaxis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
Phase 1/Phase 2 · 9 location(s) · Eledon Pharmaceuticals · NCT05027906 Anti-CD25 Monoclonal Antibody for Prevention of Acute GVHD After Haploidentical HSCT
Phase 3 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07689630 HPV Vaccine Reduced Dose
Phase 4 · 1 location(s) · Emory University · NCT06799494 Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
Phase 2 · 116 location(s) · AstraZeneca · NCT07285213 Azathioprine in MOGAD
Phase 3 · 17 location(s) · Hospices Civils de Lyon · NCT05349006 Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06880419 Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic AP
Phase N/A · 2 location(s) · Infanta Leonor University Hospital · NCT07372170 REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Particip
Phase 3 · 32 location(s) · Regeneron Pharmaceuticals · NCT07213778 IVIG for Infection Prevention After CAR-T-Cell Therapy
Phase 2 · 7 location(s) · Fred Hutchinson Cancer Center · NCT05952804 Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Canc
Phase 3 · 2 location(s) · Regeneron Pharmaceuticals · NCT07493304 Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
Phase 4 · 2 location(s) · University of Sao Paulo General Hospital · NCT07087912 A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR20
Phase 3 · 20 location(s) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. · NCT06635798 Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic H
Phase N/A · 1 location(s) · Antonello Di Paolo, M.D., Ph.D. · NCT07013370 Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
Phase 2 · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT06976476 A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Phase 3 · 42 location(s) · Takeda · NCT06980480 Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)
Phase 4 · 2 location(s) · Camille N. Kotton, MD · NCT06958796 Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Phase 2 · 17 location(s) · SCRI Development Innovations, LLC · NCT05972135 Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcinoma Patien
NA · 1 location(s) · Sheng Zhang · NCT07164950 REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
Phase 3 · 46 location(s) · Regeneron Pharmaceuticals · NCT07015905 REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Phase 3 · 13 location(s) · Regeneron Pharmaceuticals · NCT07410117

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.